References
[1] Chang GY. Research progress on aromatase and its related genes in children's growth and development. Int J Pediatr. 2010;37(3):3.
[2] Deberles E, Durand I, Mittre H, et al. Local aromatase excess with recruitment of unusual promoters of CYP19A1 gene in prepubertal patients with gynecomastia. J Pediatr Endocrinol Metab. 2022;35(7):924-30.
[3] Rui WL. Association between single nucleotide polymorphisms of CYP19A1 gene and CAG repeat sequences of AR gene with female pattern baldness in Han Chinese population [dissertation]. Shanghai: Fudan University; 2014.
[4] Liu Y. Association between single nucleotide polymorphisms of CYP19a1 gene and acne vulgaris in Han Chinese adults [dissertation]. Shanghai: Fudan University; 2012.
[5] Zhang DJ, Yuan WX, Ma LN, et al. Single nucleotide polymorphisms associated with ovulation disorders in polycystic ovary syndrome. Chin J Eugenics Genet. 2023;31(4):871-5.
[6] Wang SR, Tuoya. Research progress on gene polymorphism in endometriosis. J Med Postgrad. 2020;33(2):206-9.
[7] Liu FY. Effects of single nucleotide polymorphisms in genes such as CYP19A1 on lipid changes in postmenopausal breast cancer patients induced by nonsteroidal aromatase inhibitors [dissertation]. Beijing: Med Coll Chin PLA; 2019.
[8] Association analyzes of CYP19 gene polymorphisms with height variation in a large sample of Caucasian nuclear families. Hum Genet. 2006;120(1):119-25.
[9] Sun X, Zhu SQ. Structure and function of growth hormone. Foreign Med Sci (Physiol Pathol Clin Sci). 1999;(1):6-9.
[10] Ma HJ, Fu SC, Xiao A, et al. The associations of CYP19A1 rs700518 polymorphism with bone mineral density and risk of osteoporosis: a meta-analysis. Gynecol Endocrinol. 2020;36(7):626-31.
[11] Hawton K, Walton-Betancourth S, Rumsby G, et al. Growth Hormone With Aromatase Inhibitor May Improve Height in CYP11B1 Congenital Adrenal Hyperplasia. Pediatrics. 2017;139(2).
[12] Wang X, Liang Y, Liu Q, et al. Association of CYP19A1 Gene, Plasma Zinc, and Urinary Zinc with the Risk of Type 2 Diabetes Mellitus in a Chinese Population. Biol Trace Elem Res. 2023;201(9):4205-15.
[13] Ma JT, Zhang SZ, Yang CL, et al. Expression and significance of aromatase P450 and estrogen receptor at the endometrial-myometrial interface and lesions in adenomyosis. Chin J Matern Child Health. 2018;33(15):3529-32.
[14] Yenuganti VR, Ravinder, Singh D. Endotoxin induced TLR4 signaling downregulates CYP19A1 expression through CEBPB in buffalo granulosa cells. Toxicol In Vitro. 2017;42:93-100.
[15] Parween S, DiNardo G, Baj F, et al. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H. J Steroid Biochem Mol Biol. 2020;196:105507.
[16] Cai Y, Diao HD. Analysis of the relationship between serum TGF-β1, Apelin, CYP19A1 levels and PCOS endocrine abnormalities. J Reprod Med. 2022;31(4):463-7.
[17] Kor Y. Central precocious puberty in a case of late-diagnosed familial testotoxicosis and long-term treatment monitoring. Hormones (Athens). 2018;17(2):275-8.
[18] Shi XJ. Research progress on endometriosis and aromatase P450, estrogen receptor and its subtypes. China Med Guide. 2012;10(9):389-90.
[19] Bulun SE, Sebastian S, Takayama K, et al. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol. 2003;86(3-5):219-24.